A Cross-Sectional Study in Patients with Severe COPD to Assess the Perception of Symptom Variability (COPVAR) in the Middle East and Africa
| Autor: | Kokturk, Nurdan, Abuharbid, Wael, Albanna, Amr S., Gunen, Hakan, Gurgun, Alev, Khadadah, Mousa, Alzaabi, Ashraf |
|---|---|
| Přispěvatelé: | Ege Üniversitesi |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: | |
| Popis: | van Zyl-Smit, Richard/0000-0002-4115-5362 WOS: 000503439600001 PubMed: 31908444 Purpose: This study was performed to assess symptom variability and its impact on morning activities in stable patients with severe COPD in the Middle East and Africa (MEA) countries. Patients and methods: Non-interventional, cross-sectional study (NCT03425760) in patients with severe COPD (GOLD 2015, C, or D categories). Symptom variability was assessed directly by interviewing the patient and using the Global Chest Symptoms Questionnaire (GCSQ). the impact on morning activities was assessed using the Capacity of Daily Living during the Morning (CDLM) and the Morning Activities and Symptoms Questionnaire (MASQ). Results: A total of 3253 patients (mean +/- SD age: 64.1 +/- 9.5 years, 90.3% males) were enrolled. Overall, 81.6% and 83.4% of patients reported weekly and daily symptom variability, respectively. the number of exacerbations in the previous year, smoking cessation, and COPD GOLD D were the most consistent factors associated with symptom variability. the GCSQ score was significantly higher (p AstraZeneca (United Arab Emirates)AstraZeneca The authors would like to thank all investigators who enrolled patients in this study. To NCT (Cairo, Egypt) for clinical study management, Axonal-Biostatem (Castries, France) for data management and statistics, and Thierry Radeau Consulting (Epinay-Sous-Senart, France) for medical writing support funded by AstraZeneca (United Arab Emirates) in accordance with Good Publication Practice (GPP3) guidelines (https://www.ismpp.org/gpp3). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|